论文部分内容阅读
目的 应用血清免疫药理学技术 ,探讨环孢菌素A(CsA)对T细胞体外活化的影响 ,以进一步揭示CsA免疫调节的分子机制 ,为临床用药提供理论依据。方法 分离小鼠淋巴结细胞 ,分别与CsA、5 %CsA血清预孵后 ,加入多克隆刺激剂继续培养共 2 4h。收获细胞 ,进行双色免疫荧光标记 ,以流式细胞术分析T细胞上CD6 9分子的表达情况。结果 在CsA和 5 %CsA血清作用下 ,ConA活化的T细胞CD6 9表达的百分率分别为 (2 4 15± 3 38) %和 (2 3 6 8±6 89) % ,与相应对照组 [分别为 (6 4 6 7± 5 88) %和 (6 4 35± 10 13) % ]相比较均有显著差异 (P <0 0 1) ;在CsA和5 %CsA血清作用下 ,PDB活化的T细胞CD6 9表达的百分率分别为 (78 86± 7 70 ) %和 (80 0 5± 9 91) % ,与相应对照组 [分别为 (84 79± 6 87) %和 (79 6 8± 4 17) % ]相比较均无显著差异 (P >0 0 5 )。结论 CsA(410nmol/L)和含CsA血清均可强烈抑制ConA刺激的T细胞活化 ,而对PDB刺激的T细胞活化无抑制效应。 5 %CsA血清与CsA单纯药物体外实验的结果相一致 ,在一定程度上反映了临床等效剂量下血清免疫药理技术的有效性与可行性
Objective To investigate the effect of cyclosporin A (CsA) on the activation of T cells in vitro by using serum immunopharmacological techniques to further reveal the molecular mechanism of CsA immunoregulation and provide a theoretical basis for clinical drug use. Methods Mouse lymph node cells were isolated and preincubated with CsA and 5% CsA respectively. The polyclonal stimulators were added to continue the culture for 24 hours. The cells were harvested and labeled with two-color immunofluorescence. The expression of CD6 9 on T cells was analyzed by flow cytometry. Results The percentage of CD6 9 expression in ConA-activated T cells was (2 4 15 ± 3 38)% and (2 3 6 8 ± 6 89)%, respectively, compared with the corresponding control group [ (6 4 6 7 ± 5 88)% and (6 4 35 ± 10 13)%], respectively (P 0 01). Under the action of CsA and 5% CsA serum, the activation of T The percentage of CD6 9 expression was (78 86 ± 7 70)% and (80 0 5 ± 9 91)%, respectively, compared with the corresponding control group [84 79 ± 6 87% and 79 6 8 ± 4 17 )%] Compared to no significant difference (P> 0 0 5). Conclusions Both CsA (410 nmol / L) and CsA serum can strongly inhibit the activation of ConA-stimulated T cells but not the activation of PDB-stimulated T cells. The consistency of 5% CsA serum with the results of CsA pure drug in vitro experiments to a certain extent reflects the effectiveness and feasibility of serum immunopharmacological technology in clinical equivalent dose